



## ASX ANNOUNCEMENT

25 OCTOBER 2018

### CANN SIGNS RESEARCH & DEVELOPMENT AGREEMENT WITH CSIRO

---

**25 October 2018** – Cann Group Limited (ASX: CAN) has signed a broad, three-year agreement with the Commonwealth Scientific and Industrial Research Organisation (CSIRO) to extend its research and development collaboration.

Cann will work with multiple CSIRO business units under the new umbrella agreement, which will see technology development activities undertaken for use in the commercial manufacture and sale of medicinal cannabis products.

Under the terms of the agreement, all resulting intellectual property will be owned by Cann.

Cann Group CEO Peter Crock said having the support and involvement of Australia's flagship research organisation is a coup for the Company.

"Our strong ongoing commitment to building a science-based business will be complemented by the outstanding facilities, skills and experience that CSIRO will contribute to the collaboration. This agreement will enable us to investigate numerous opportunities across medicinal cannabis technologies," he said.

CSIRO Manufacturing Deputy Director, Dr Paul Savage, said CSIRO is looking forward to working on a range of research areas associated with the emerging market demand for novel medicinal cannabis treatments and delivery systems.

"The growing medicinal cannabis sector provides an exciting new frontier for medical research and we are delighted to be involved with Cann Group.

"Medicinal cannabis is gaining greater support in various geographies around the world, yet there is still much to be learned from a scientific perspective. With our history and capability in medical research, and the support of a local industry leader like Cann Group, we expect to be able to make significant discoveries in this developing sector."

**For further information please contact:**

Peter Crock  
Cann Group Limited  
+61 (0) 3 9095 7088  
[contact@canngrouplimited.com](mailto:contact@canngrouplimited.com)

Matthew Wright  
NWR Communications  
+61 (0) 451 896 420  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

**About Cann Group**

Cann Group is building a world-class business focused on breeding, cultivating and manufacturing medicinal cannabis for sale and use within Australia. The company has established research and cultivation facilities in

Melbourne and is striving to provide access to medicinal cannabis for Australian patients. Cann Group has executed collaboration agreements that will enable it to establish a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. It was issued with Australia's first medicinal cannabis research licence in February 2017, in addition to Australia's first medicinal cannabis cultivation licence in March 2017. Aurora Cannabis Inc – one of Canada's largest listed medicinal cannabis company – is a cornerstone investor in Cann, with a 22.9% shareholding.

**About CSIRO**

CSIRO is Australia's national science agency and one of the largest and most diverse research agencies in the world. Its innovations contribute billions of dollars to the Australian economy every year. As the largest patent holder in the nation, CSIRO's wealth of intellectual property has led to more than 150 spin-off companies.